Skip to content
SmartFigure
Nippon India Mutual Fund

Nippon India Pharma Fund

Nippon India Mutual Fund · Direct plan · Growth

3-year returns
18.6%
a year
NAV
₹643.73
▲ 0.87% · 18 Sept 2026
Fund size
₹9,479 Cr
Expense ratio
1%
a year
Minimum SIP
₹100

Figures are for the Direct plan. The Regular plan, bought through a distributor, is at ₹572.02 and has returned 17.51% a year over 3 years.

Returns, and where it stands

Against the average sectoral / thematic fund, and its place among them. Anything longer than a year is a yearly rate.

PeriodThis fundCategoryRank
1 year10.6%5.2%ahead62 of 221
3 years18.6%14.5%ahead36 of 136
5 years13.8%12.9%ahead38 of 98
10 years15.7%14.5%ahead25 of 68
Every period, and the Regular plan →
PeriodDirectRegular
1 month0.1%0%
3 months6.3%6%
6 months14.2%13.8%
1 year10.6%9.7%
2 yearsp.a.6%5.1%
3 yearsp.a.18.6%17.5%
5 yearsp.a.13.8%12.8%
7 yearsp.a.23.2%22.1%
10 yearsp.a.15.7%14.7%

Figures are for the Direct plan, and the rank compares it against the same plan of its peers, best first. Based on NAV history from Sept 2016.

Plan

NAV history

▲ 10.63% in the last 1Y

540.7596.4652.118 Sept 202520 Mar 202618 Sept 2026

Hover or tap the chart for the NAV on any date. Past NAVs are adjusted for unit splits.

If you had invested in this fund

Investment type
years
Total invested
₹1,80,000
Gain
₹40,680
XIRR (per year)
13.73%
Value today
₹2,20,680

36 monthly instalments from 22 Sept 2023, valued at the latest NAV. Past returns do not guarantee future returns.

What the ride has been like

Worked out from this fund's own NAV history, not a rating.

How bumpy
13% a year
2.6% less than the category average — the steadier side
Worst fall so far
−21.2%
Feb 2020 to Mar 2020, against −25.3% for the category.
Years that made money
78.4%
Of every one-year stretch it has been through.
Over any three years
-1.3% to 32.2%
A year, at worst and at best. Typically 20.3%.

Fund details

Minimum lumpsum
₹5,000
Minimum top-up
₹1,000
Lock-in
None
Plan started
1 Jan 2013
Portfolio turnover
0.15x
Expense ratio
1%
as of 31 Jul 2026

Managed by Sailesh Raj Bhan, Kinjal Desai, Amber Singhania

Direct plan figures, last checked on 20 Sept 2026. Exit load and the scheme's benchmark are in thescheme document.

How it compares

Nippon India Pharma Fund against other funds in the Sectoral / Thematic Fund category
Fund1Y3Y5YExpenseFund size
Nippon India Taiwan Equity Fund118%61.43%1.24%₹1,128 Cr
HDFC Defence Fund21.09%37.07%0.9%₹11,478 Cr
HDFC Transportation and Logistics Fund7.35%24.8%1.09%₹2,116 Cr
SBI Healthcare Opportunities Fund20.88%24.31%18.52%1.02%₹5,796 Cr
UTI - Healthcare Fund16.82%24.15%16.09%1.28%₹1,444 Cr
LIC MF Infrastructure Fund8.97%23.9%21.88%1.35%₹1,174 Cr
Nippon India Pharma Fund10.63%18.57%13.78%1%₹9,479 Cr

About Nippon India Pharma Fund

Nippon India Pharma Fund is a sectoral / thematic fund managed by Nippon India Mutual Fund. Invest in one sector (such as banking, IT or pharma) or a theme (such as consumption or infrastructure). Concentrated and higher risk; suited to investors with a view on that sector.

The primary investment objective of the scheme is to seek to generate consistent returns by investing in equity and equity related or fixed income securities of Pharma and other associated companies.

The scheme's stated objective, as published by Nippon India Mutual Fund.

The NAV (net asset value) is the price of one unit of the fund. It is published by the fund house every business day and changes with the value of the fund's holdings. The Growth option reinvests all gains, so its NAV reflects the fund's total return.

Tax on your gains

Gains are taxed as equity: sell within 12 months and the gain is short-term, taxed at 20%. Hold longer and it is long-term, taxed at 12.5% on gains above ₹1.25 lakh in a financial year, across all your equity investments.

Work out what you would owe with the capital gains tax calculator.

Every plan and option, with scheme codes
PlanOptionNAVScheme code
DirectGrowth Option₹643.7329118759
DirectBonus Option₹643.7329118758
DirectIDCW Option₹176.1761118756
RegularGrowth Option₹572.0189102431
RegularBonus Option₹572.0189102432
RegularIDCW Option₹123.5241102433

Frequently asked questions

What is the NAV of Nippon India Pharma Fund today?

The NAV of Nippon India Pharma Fund (Direct plan, Growth) is ₹643.7329 and the Regular plan NAV is ₹572.0189, as of 18 Sept 2026.

What returns has Nippon India Pharma Fund given?

Over the last year the Direct plan returned 10.63%, and 18.57% a year over 3 years and 13.78% a year over 5 years. That places it 36 of 136 funds in its category over 3 years. Past returns do not guarantee future returns.

What is the expense ratio of Nippon India Pharma Fund?

The Direct plan charges 1% a year, as disclosed on 31 Jul 2026. The fee is already taken out of the NAV, so the returns above are what you keep.

What is the minimum SIP amount in Nippon India Pharma Fund?

You can start a monthly SIP with ₹100, or invest a lump sum of ₹5,000 or more.

How much has Nippon India Pharma Fund fallen in the past?

Its deepest fall was 21.2% from 19 Feb 2020 to 23 Mar 2020. Of every one-year stretch in its history, 78% ended in a gain.

Which category does Nippon India Pharma Fund belong to?

It is a Sectoral / Thematic Fund from Nippon India Mutual Fund. Invest in one sector (such as banking, IT or pharma) or a theme (such as consumption or infrastructure). Concentrated and higher risk; suited to investors with a view on that sector.

What is the difference between the Direct and Regular plan?

Both invest in the same portfolio. The Direct plan is bought straight from the fund house or a direct platform and has a lower expense ratio because no distributor commission is paid, so its NAV grows slightly faster over time.

How are gains from Nippon India Pharma Fund taxed?

Gains are taxed as equity: sell within 12 months and the gain is short-term, taxed at 20%. Hold longer and it is long-term, taxed at 12.5% on gains above ₹1.25 lakh in a financial year, across all your equity investments.

Source: NAVs published by the fund house through AMFI. Mutual fund investments are subject to market risks; read all scheme-related documents carefully. Past performance does not guarantee future returns. This page is for information only and is not a recommendation to buy or sell.